Roger D. Hurst, age 55, founded AspenBio Pharmaceuticals in July 2000, serving as the Company's President and principal shareholder. He provided the initial capital of $470,000 to acquire the antigen business from Vitro Diagnostics, Inc., and contributed approximately $625,000 in debt financing for facility construction in Castle Rock, Colorado. His employment agreement provided for annual compensation of $100,000.
Hurst served as Chief Executive Officer, Secretary and Director through December 2004, when he resigned from officer and director positions. The Company terminated his employment effective September 2, 2005. He received annual compensation of $72,000 (2002), $64,500 (2003), and $88,833 (2004). In July 2004, Hurst contributed 1,896,757 shares of common stock back to the Company for no consideration pursuant to an April 2004 equity fundraising agreement.
Biography extracted from Riot DEF 14A filed 2005-09-26 View cached copy (2026-09-27)Live source ↗
Roles
Contiguous filings for the same role are collapsed into a single tenure span. Click a row to see the underlying filings.
| Company | Role | Tenure | Filings |
|---|---|---|---|
| Riot | President, Director, 10%+ Owner | 2003-09 → present (23y 2mo) | 3 |
Show 3 underlying filings | |||
| Riot | 10%+ Owner | 2006-02 → present (20y 9mo) | 7 |
Show 7 underlying filings | |||
Insider transactions
Totals for this person
| Bucket | Invested (shares) | Invested (USD) | Divested (shares) | Divested (USD) | Net direction | Txns | Invested @ last price | Divested @ last price |
|---|---|---|---|---|---|---|---|---|
| All time | 225,643 | $363.2K | 2,246,757 | $0 | ↑ Invested $363.2K | 11 | $2.89M | $28.78M |
| 2006 | 220,500 | $360.2K | - | $0 | ↑ Invested $360.2K | 8 | $2.82M | $0 |
| 2004 | 5,143 | $3.0K | 1,896,757 | $0 | ↑ Invested $3.0K | 2 | $65.9K | $24.30M |
| 2003 | - | $0 | 350,000 | $0 | Flat | 1 | $0 | $4.48M |
| 2004-Q3 | 5,143 | $3.0K | 1,896,757 | $0 | ↑ Invested $3.0K | 2 | $65.9K | $24.30M |
| 2006-Q1 | 124,000 | $222.0K | - | $0 | ↑ Invested $222.0K | 1 | $1.59M | $0 |
| 2006-Q2 | 5,000 | $7.2K | - | $0 | ↑ Invested $7.2K | 2 | $64.0K | $0 |
| 2006-Q3 | 91,500 | $131.1K | - | $0 | ↑ Invested $131.1K | 5 | $1.17M | $0 |
Invested = shares acquired (buys, grants, option exercises) — insider adding to the position. Divested = shares reduced (sells, dispositions, tax-withholding) — cash flowing TO the insider. Net direction shows which side wins on dollar terms in each bucket. % of holder's stake not yet computed (pending Form 3/4 holdings ingest). See methodology. The two @ last price columns restate the same share counts at the most recent share price we read (close of 2026-10-30); they are a valuation, not a cash flow, and they move every day the market does.
All transactions
| Date | Company | Kind | Shares | Amount (USD) | Value @ last price |
|---|---|---|---|---|---|
| 2006-08-09 | Riot | Open-market purchase · AspenBio Pharma | 15,000 | $21,150 | $192.2K |
| 2006-08-09 | Riot | Open-market purchase · AspenBio Pharma | 2,000 | $2,860 | $25.6K |
| 2006-08-08 | Riot | Open-market purchase · AspenBio Pharma | 46,500 | $66,030 | $595.7K |
| 2006-07-31 | Riot | Open-market purchase · AspenBio Pharma | 10,500 | $16,170 | $134.5K |
| 2006-07-26 | Riot | Open-market purchase · AspenBio Pharma | 17,500 | $24,850 | $224.2K |
| 2006-06-22 | Riot | Open-market purchase · AspenBio Pharma | 1,000 | $1,600 | $12.8K |
| 2006-06-15 | Riot | Open-market purchase · AspenBio Pharma | 4,000 | $5,600 | $51.2K |
| 2006-03-07 | Riot | Open-market purchase · AspenBio Pharma | 124,000 | $221,960 | $1.59M |
| 2004-08-31 | Riot | Open-market purchase | 5,143 | $2,983 | $65.9K |
| 2004-07-21 | Riot | Sale to issuer (buyback) | 1,896,757 | - | $24.30M |
| 2003-09-30 | Riot | Sale to issuer (buyback) · Common tock | 350,000 | - | $4.48M |